Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026
Company Deals

AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products

Fineline Cube Apr 17, 2026
Company Deals

Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform

Fineline Cube Apr 17, 2026
Company Deals

Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu

Fineline Cube Apr 17, 2026
Company Deals Digital

Tigermed and Alibaba Cloud Forge Alliance to Build AI-Powered Ecosystem for Intelligent Clinical Trials

Fineline Cube Apr 17, 2026
Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Fineline Cube Apr 20, 2026
Company Drug

Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026

Fineline Cube Apr 20, 2026
Company Drug

Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026

Fineline Cube Apr 20, 2026
Company Legal / IP

Luye Pharma’s Paliperidone Palmitate NDA Avoids Patent Lawsuit, Clears Path for FDA Approval

Fineline Cube Feb 4, 2024

Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced that the New Drug...

Company Deals

Matridx Bio Secures Series C+ Funding to Advance Infectious Pathogens Diagnostics

Fineline Cube Feb 4, 2024

Hangzhou Matridx Biotechnology Co., Ltd, a specialist in molecular diagnostics for infectious pathogens based in...

Company Deals Drug

China Medical System Reclaims Rights to Velphoro from WinHealth in Greater China

Fineline Cube Feb 4, 2024

China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a rights assignment agreement with...

Company Drug

Sichuan’s Ancocare Gets FDA Green Light for Phase I/III Study of Oncolytic Virus in Neuroblastoma

Fineline Cube Feb 4, 2024

Sichuan-based Flavivirus technology platform developer Ancocare has announced that it has received approval from the...

Company

Siemens Healthineers Posts 5.7% Q1 2024 Sales Growth, Exceeds Pre-Pandemic Levels

Fineline Cube Feb 4, 2024

Siemens Healthineers AG (ETR: SHL), based in Germany, has released its quarterly report for the...

Company Drug

Roche Posts Modest 2023 Growth Amid Shifts in Demand for COVID-Related Products

Fineline Cube Feb 4, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has published its 2023 financial results, showing a modest...

Company Deals

Teva Pharmaceuticals Initiates Spin-off of TAPI Unit, Targeting 2025 for Completion

Fineline Cube Feb 2, 2024

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) a transnational generic drugs giant with Israeli and U.S....

Company Drug

Merck KGaA’s Tepmetko Launches in China, Expanding Access to MET Inhibitor for Lung Cancer Patients

Fineline Cube Feb 2, 2024

Merck KGaA (NYSE: MRK), a leading German science and technology company, has announced the commercial...

Company Deals

Chia Tai Tianqing and Fudan University Shanghai Cancer Center Join Forces for Innovative Drug Development

Fineline Cube Feb 2, 2024

Chia Tai Tianqing, a China-based pharmaceutical company, has entered into a strategic partnership with Fudan...

Company

Takeda Secures Rights to Protagonist Therapeutics’ Rusfertide in Landmark Deal

Fineline Cube Feb 2, 2024

Takeda Pharmaceuticals Company Limited (TYO: 4502) has announced a significant expansion of its hematology portfolio...

Company Drug

Shanghai Junshi Biosciences’ Toripalimab Aims for Singapore Approval in Nasopharyngeal Carcinoma

Fineline Cube Feb 2, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...

Company

Novo Nordisk Delivers Strong 2023 Results with Record-Breaking Sales

Fineline Cube Feb 2, 2024

Novo Nordisk A/S (NYSE: NVO), a Denmark-based pharmaceutical company, has announced its financial results for...

Company

Sanofi Reports Full-Year Revenue Growth Driven by Dupixent and Vaccines, Eyes Biopharma Focus

Fineline Cube Feb 2, 2024

Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its financial report for the...

Company Drug

Takeda Reports Flat 9-Month Revenue Growth Amid Pipeline Optimization Efforts

Fineline Cube Feb 2, 2024

Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has released its financial results for the...

Company

Merck Q4 Sales Grow 6% YOY, Driven by Pharmaceutical Segment and HPV Vaccine Demand

Fineline Cube Feb 2, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading US pharmaceutical company, has released its...

Company Deals

Sanofi Secures Rights to Graviton’s ROCK2 Inhibitor Candidates in Strategic Biotechnology Investment

Fineline Cube Feb 2, 2024

Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has made an undisclosed investment in biotechnology...

Policy / Regulatory

NHSA Launches Service Specifications for Medical Procurement Platform

Fineline Cube Feb 2, 2024

The National Healthcare Security Administration (NHSA) has issued the “Service Specification for Medical Centralized Procurement...

Policy / Regulatory

China’s NHC Unveils 2024 Goals for Medical Quality and Safety Improvement

Fineline Cube Feb 2, 2024

The National Health Commission (NHC) has released the “2024 National Medical Quality and Safety Improvement...

Company

WuXi Biologics Achieves Full-Scale Manufacturing Milestone at Ireland Facility

Fineline Cube Feb 1, 2024

WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...

Company Deals

HitGen Inc. and Bostal Drug Delivery Form Strategic Partnership to Advance Nucleic Acid Drug Development

Fineline Cube Feb 1, 2024

HitGen Inc. (SHA: 688222), a China-based company, has announced a strategic partnership with Bostal Drug...

Posts pagination

1 … 392 393 394 … 653

Recent updates

  • China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores
  • Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026
  • Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026
  • Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio
  • AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Company Drug

Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026

Company Drug

Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026

Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.